Fundamentals
Global Blood Therapeutics (GBT) most recent 10-Q
Capital structure
The company is well-funded and should be sufficient to fund the initial marketization up until the full approval of Voxelotor. I theorize that this would be the best time to capitalize in the form of dilution for the company and shareholders.
Risks: Any delay in the regulatory process may require the company to raise, again, at cost-disadvantageous prices. Likewise, a failed confirmatory trial would be disastrous to Global Blood's valuation.
Chart
GBT's share price demonstrates strong support in the mid-$40's, presenting a good